Mexico and Canada 
Outside North America 
US 
CAT #: 13100010
BCR/ABL t(9;22) Translocation Assay for Gel Detection
Assay Use
This Research Use Only assay identifies BCR/ABL t(9;22) translocations.
Product Details
-
Summary and Explanation of the Test
BACKGROUND
BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnormality that results from reciprocal t(9;22)(q34;ql1) chromosomal rearrangements fuse coding regions of the BCR gene, located on chromosome 22, with the ABL receptor-independent tyrosine kinase gene on chromosome 9. This assay detects and identifies the variety of p190-, p210- and p230-type transcripts produced from all known BCR/ABL translocations.SUMMARY
The master mixes are included in these assay kits used to amplify complementary DNA (cDNA) produced from specimen(s), and positive and negative RNA controls (included). Primers target an internal control transcript (Abl) and p190-, p210-, and p230-type transcripts expressed from BCR-ABL1 translocations. Amplicon products can be analyzed by capillary electrophoresis or standard gel electrophoresis with ethidium bromide staining. This assay is compatible with all standard RNA extraction and cDNA synthesis methods. -
Specimen Requirements
This assay tests complementary DNA (cDNA) template.
Legal Notice
Warranty and Liability
Invivoscribe, Inc. (Invivoscribe®) is committed to providing the highest quality products. Invivoscribe® warrants that the products meet or exceed the performance standards described in the Instructions For Use, as to products with such an insert. If a product is covered by product specifications and does not perform as specified, our policy is to replace the product or credit the full purchase price. No other warranties of any kind, expressed or implied, are provided by Invivoscribe®. Invivoscribe® liability shall not exceed the purchase price of the product. Invivoscribe® shall have no liability for direct, indirect, consequential or incidental damages arising from the use, results of use, or inability to use its products; product efficacy under purchaser controlled conditions in purchaser’s laboratory must be established and continually monitored through purchaser defined and controlled processes including but not limited to testing of positive, negative, and blank controls every time a sample is tested. Ordering, acceptance, and use of product constitutes purchaser acceptance of sole responsibility for assuring product efficacy and purchaser agreement to the limitation of liability set forth in this paragraph.
This product is for Research Use Only; not for use in diagnostic procedures.
This product is covered by one or more of the following: European Patent Number 1549764, European Patent Number 2418287, European Patent Number 2460889, Japanese Patent Number 4708029, United States Patent 8859748, United States Patent 10280462, and related pending and future applications. All of these patents and applications are licensed exclusively to Invivoscribe®. Additional patents licensed to Invivoscribe® covering some of these products apply elsewhere. Many of these products require nucleic acid amplification methods such as Polymerase Chain Reaction (PCR). No license under these patents to use amplification processes or enzymes is conveyed expressly or by implication to the purchaser by the purchase of this product.
©2020 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.